Evolving Standards in Prostate Cancer: Lessons From ESMO 2025

Read the full interview on Oncology Data Advisor: https://oncdata.com/stephen-freedland-murilo-luz-esmo-2025 At ESMO 2025, new data challenged and refined treatment standards in prostate cancer. In this interview, Stephen Freedland, MD, and Murilo Luz, MD, discuss why the Enza A trial failed to show benefit for adding enzalutamide to ADT plus radiation in high-risk localized disease, highlighting the impact of very low event rates and “wrong population” rather than a “bad drug.” They then review the evolving triplet landscape in metastatic castration-sensitive prostate cancer, including PARP inhibitor–based regimens such as AMPLITUDE and the PSMA Addition trial of lutetium PSMA plus ADT and an AR pathway inhibitor, and what these results mean for selecting patients rather than intensifying therapy for everyone. Finally, they touch on CAPItello and capivasertib in PTEN-deficient disease as a signal of where biomarker-driven triplets are headed. #ProstateCancer #ESMO2025 #EnzaA #PSMAAddition #AMPLITUDE #CAPItello #LutetiumPSMA #PARPInhibitors #PTENLoss #PrecisionOncology